|
|
| | NMS-P626 Basic information |
| Product Name: | NMS-P626 | | Synonyms: | NMS-P626;Benzamide, N-[5-[(3,5-difluorophenyl)sulfonyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-[[(1R)-2-methoxy-1-methylethyl]amino]-4-(4-methyl-1-piperazinyl)- | | CAS: | 942471-37-6 | | MF: | C28H35F2N7O4S | | MW: | 603.69 | | EINECS: | | | Product Categories: | | | Mol File: | 942471-37-6.mol |  |
| | NMS-P626 Chemical Properties |
| density | 1.396±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 12.545±0.20(predicted) |
| | NMS-P626 Usage And Synthesis |
| Uses | NMS-P626 is an inhibitor of TRKA, TRKB, and TRKC, with IC50 values of 8 nM, 7 nM, and 3 nM, respectively. NMS-P626 inhibits the growth of KM12 cells by suppressing the phosphorylation of TPM3-TRKA and downstream signaling in KM12 cells, with an IC50 of 19 nM for KM12 cells. NMS-P626 can be used in colorectal cancer research[1]. | | IC 50 | TrkA: 8 nM (IC50); TrkB: 3 nM (IC50); TrkC: 7 nM (IC50) | | References | [1] Ardini E, et al. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol. 2014 Dec;8(8):1495-507. DOI:10.1016/j.molonc.2014.06.001 |
| | NMS-P626 Preparation Products And Raw materials |
|